News Mixed results for experimental Alzheimer's therapies at CTAD The CTAD Alzheimer's meeting hears encouraging data for new drug candidates from the likes of Biogen, AriBio, and BMS - but also some disappointments.
News UK's Oyster Tx rebrands and raises $60m for Alzheimer's R&D UK start-up Oyster Therapeutics has raised $60m in first-round financing for its novel take on protein degraders, starting with tau in Alzheimer's.
News UK trial 'could halve time to test Alzheimer's drugs' A pioneering UK study, AD-SMART, will test multiple repurposed and new drugs in parallel to try to slash the time it takes to gauge their efficacy.
R&D Alzheimer’s: Starting the impossible journey September was Alzheimer’s Month, and with that in mind pharmaphorum spoke to leaders at two biotechs about latest developments in the field.
News UK puts £80m behind dementia diagnosis push The UK is putting £80 million ($105 million) in funding behind nine technologies that it hopes will be able to diagnose dementia more quickly.
News UK needs 'clearer path for dementia diagnosis and treatment' UK Prime Minister Andy Burnham, who lost his father to Alzheimer's last week, has been urged to implement a "cancer-style" reform of dementia care.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.